Katherine Pawelczak
Chief Operating Officer & Vice President - Research Nerx BioSciences Inc.
Seminars
Wednesday 28th January 2026
Targeting Ku-DNA Binding to Improve Specificity, Reduce Toxicity & Advance Next-Generation DDR Therapeutics
1:45 pm
• Introducing Ku as the first responder to DNA double-strand breaks and a novel DDR target distinct from kinase inhibitors
• See how Nerx BioSciences are disrupting Ku-DNA interactions to block DNA-PK activity with greater specificity and reduced toxicity
• Demonstrating how this upstream approach could deliver safer and more effective DDR therapies compared to traditional kinase inhibition
